Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 2/20 | 0.32 |
| ▸ | GSK3A | P49840 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL194207 | 0.73 | — | — | |
| SCHEMBL666590 | 0.69 | — | — | |
| SCHEMBL2639486 | 0.65 | MGLL (0.50) | SMN1; SMN2MGLLGSK3AGSK3BFAAH | |
| SCHEMBL4375225 | 0.65 | CA12 (0.47) | SMN1; SMN2 | |
| SCHEMBL6302015 | 0.65 | NPC1 (0.42) | SMN1; SMN2 | |
| SCHEMBL9813218 | 0.65 | SMN1; SMN2 (0.39) | SMN1; SMN2 | |
| SCHEMBL17233963 | 0.64 | — | — | |
| SCHEMBL6211097 | 0.63 | HSP90AA1 (0.32) | MGLLGSK3AGSK3B | |
| SCHEMBL9813226 | 0.63 | SMN1; SMN2 (0.38) | SMN1; SMN2 | |
| SCHEMBL4602946 | 0.62 | CA12 (0.51) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8134013-B2 | Amide compound and thrombopoietin receptor activator | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-03-13 | — | — | US | claimed |
| US-4533730-A | BACTERICIDES | SHIONOGI & CO., LTD. (JP) | 1985-08-06 | — | — | US | claimed |
| US-4478997-A | 1-Oxadethiacepham compounds | SHIONOGI & CO., LTD. (JP) | 1984-10-23 | — | — | US | claimed |
| US-4443598-A | ANTIBIOTICS AND INTERMEDIATES | SHIONOGI & CO., LTD. (JP) | 1984-04-17 | — | — | US | claimed |
| US-4066641-A | METHOD FOR CYCLIZATION TO GIVE CEPHEM RING | HAMASHIMA YOSHIO | 1978-01-03 | — | — | US | claimed |
| US-20040067999-A1 | Carbazole derivatives and their use as neuropeptide y5 receptor ligands | ASTRAZENECA AB (SE) | 2004-04-08 | — | — | US | disclosed |
| EP-1358157-A1 | CARBAZOLE DERIVATIVES AND THEIR USE AS NEUROPEPTIDE Y5 RECEPTOR LIGANDS | AstraZeneca AB (SE) | 2003-11-05 | — | — | EP | disclosed |
| WO-2002051806-A1 | CARBAZOLE DERIVATIVES AND THEIR USE AS NEUROPEPTIDE Y5 RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2002-07-04 | — | — | WO | disclosed |
| US-4604460-A | ANTIBIOTICS, BACTERICIDES | SHIONOGI & CO., LTD. (JP) | 1986-08-05 | — | — | US | disclosed |
| US-4533730-A | BACTERICIDES | SHIONOGI & CO., LTD. (JP) | 1985-08-06 | — | — | US | disclosed |
| US-4504659-A | 1-Oxadethiacepham compounds | SHIONOGI & CO., LTD. (JP) | 1985-03-12 | — | — | US | disclosed |
| US-4478997-A | 1-Oxadethiacepham compounds | SHIONOGI & CO., LTD. (JP) | 1984-10-23 | — | — | US | disclosed |
| US-4443598-A | ANTIBIOTICS AND INTERMEDIATES | SHIONOGI & CO., LTD. (JP) | 1984-04-17 | — | — | US | disclosed |
| US-4366316-A | FROM OXAZOLINOAZETIDINONE AND ACID | SHIONOGI & CO., LTD. (JP) | 1982-12-28 | — | — | US | disclosed |
| US-4283333-A | α-[4-Oxoazetidin-1-yl]-acetic acid compounds useful as intermediates in preparing 1-oxadethiacephalosporins | SHIONOGI & CO., LTD. (JP) | 1981-08-11 | — | — | US | disclosed |
| US-4269773-A | CEPHALOSPORINS | SHIONOGI & CO., LTD. (JP) | 1981-05-26 | — | — | US | disclosed |
| US-4223132-A | Selective conversion of benzyl alcohol carboxylates to the free acid form | SHIONOGI & CO., LTD. (JP) | 1980-09-16 | — | — | US | disclosed |
| US-4159984-A | METAL AND PROTON DONOR | SHIONOGI & CO., LTD. (JP) | 1979-07-03 | — | — | US | disclosed |
| US-4066641-A | METHOD FOR CYCLIZATION TO GIVE CEPHEM RING | HAMASHIMA YOSHIO | 1978-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067999-A1 | Carbazole derivatives and their use as neuropeptide y5 receptor ligands | NPY5R, NPY1R, NPY2R | SMN1; SMN2 3995/4885MGLL 3009/4885GSK3A 1392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.